Erythropoietin (EPO) Global Market Report 2024

The erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $19.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historic period can be attributed to several factors, including increased patient education and awareness, consolidation within the pharmaceutical industry, policies related to healthcare reimbursement, expansion of the market coupled with demand growth, and the impact of patent expiration and entry of biosimilar products.

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The forecasted growth is driven by market competition, biosimilar impact, disease prevalence projections, healthcare policy changes, emerging markets, and increased focus on clinical trials. Key trends include supply chain management advancements, global expansion, patient education, reimbursement policy evolution, and industry consolidation.

The increasing prevalence of chronic kidney diseases is expected to drive the demand for erythropoietin in the market. The rise in cases of chronic kidney disease necessitates the administration of erythropoietin, which stimulates the production of red blood cells, aiding in immune improvement. A report from the Centers for Disease Control and Prevention in March 2021 revealed that approximately 15% of adults in the United States, equating to 37 million people, were estimated to have chronic kidney disease (CKD). The prevalence is higher among individuals aged 65 or older (38%), followed by those aged 45-64 (13%), and those aged 18-44 (7%). The anemia conditions resulting from chronic kidney diseases contribute to an increased demand for erythropoietin, thereby fostering market growth.

The growth of the erythropoietin market may be hindered by stringent regulations governing the production and sales of erythropoietin drugs. In the European Community (EC), advanced medicinal products, especially those manufactured using biotechnological processes such as recombinant DNA technology, must comply with marketing authorization (MA) regulations outlined in Regulation (EC) No. 726/04 issued by the EC. The regulatory landscape for biosimilars, including erythropoietin, is intricate and primarily governed by guidelines established by the European Medicines Agency (EMEA). Additionally, recombinant human erythropoietin (rHuEPO) must adhere to specific guidelines within its product class, in addition to regulations covering quality, clinical, and non-clinical aspects, as defined by the EMEA.

The anticipated growth of the erythropoietin market is expected to be driven by the increasing incidence of hematologic cancer. Hematologic cancer constitutes a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a crucial role in managing cancer-related anemia by stimulating the production of red blood cells, thereby alleviating anemia in cancer patients, particularly those undergoing chemotherapy. For instance, in 2023, the American Cancer Society estimates that leukemia is expected to affect 59,610 Americans and cause 23,710 deaths. Additionally, new cases of non-Hodgkin lymphoma are projected to impact 80,550 people in the United States, resulting in 20,180 deaths. Consequently, the increasing prevalence of hematologic cancers is driving the forward momentum of the erythropoietin market.

Major players in the erythropoietin market are introducing innovative products such as Yi Bao (Human Erythropoietin for Injection) to drive business growth, enhance productivity, and explore new markets. Yi Bao is a recombinant human erythropoietin produced using CHO cells. Wanbang Biopharmaceuticals Co. Ltd., a China-based pharmaceutical company, obtained approval from the National Medical Products Administration (NMPA) in September 2021 for Yi Bao's use in treating anemia caused by chemotherapy in patients with non-myeloid malignancies. Yi Bao closely resembles the imported innovator drug, exhibiting precise efficacy and fewer side effects.

Major players in the erythropoietin market are innovating with products such as Varenzin-CA1 to solidify their market position. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA designed to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Elanco, a US-based pharmaceutical company, secured FDA approval for Varenzin-CA1 in May 2023. This breakthrough innovation for cats boasts a unique mode of action that triggers the genetic transcription of erythropoietin (EPO), leading to increased EPO and red blood cell production in a cat's body. Varenzin-CA1 sets a new standard of care for cats experiencing nonregenerative anemia due to CKD, offering convenience for at-home use.

Major companies operating in the erythropoietin (epo) market report are BASF SE, Hoffmann-La Roche AG, Merck Sharp & Dohme LLC, Sanofi SA, Thermo Fisher Scientific Inc., Associated British Foods PLC, DuPont de Nemours Inc., Kerry Group PLC, Firmenich SA, Koninklijke DSM NV, Dyadic International Inc., Novozymes A/S, Endo International PLC, Chr Hansen Holding A/S, Advanced Enzyme Technologies Ltd., Catalyst Pharmaceuticals Inc., Codexis Inc., AB Enzymes GmbH, Brain Biotech AG, Biocatalysts Ltd., Xike Biotechnology Co. Ltd., Amano Enzyme Inc., Enzyme Development Corporation, Lumis Biotech Pvt. Ltd., Teknisk-Kemiske Laboratorium ApS, Creative Enzymes Co. Ltd., BioResource International Inc., Enzyme Bioscience Pvt. Ltd., Sunson Industry Group Co. Ltd.

North America was the largest region in the erythropoietin (EPO) market in 2023. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of erythropoietin products include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin that is synthesized in cell culture. Erythropoietin falls into different drug classes, including biologics and biosimilars, and finds applications in various medical fields such as cancer, hematology, renal diseases, neurology, and others.

The erythropoietin (EPO) market research report is one of a series of new reports that provides erythropoietin (EPO) market statistics, including erythropoietin (EPO) industry global market size, regional shares, competitors with an erythropoietin (EPO) market share, detailed erythropoietin (EPO) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (EPO) industry. This erythropoietin (EPO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.